By Deena Beasley (Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' ...

CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties.

CVS Health (NYSE:CVS), one of the leading health insurers in the U.S. and owner of the Pharmacy Benefit Manager Caremark, ...

Gilead Sciences (NASDAQ:GILD) stock fell 2.7% in pre-market trading Thursday after reports that CVS Health (NYSE:CVS) will not add the company’s new HIV prevention drug, Yeztugo, to its commercial ...

Investing.com -- CVS Health (NYSE: CVS) will not include Gilead Sciences (NASDAQ: GILD )’ new HIV prevention drug Yeztugo in its commercial plans for the time being, despite the medication’s proven ...

Dividend Growth: CVS has increased its dividend by 142% over the past decade, with a current forward yield of 4.64%. This significantly surpasses the S&P 500 average of 1.35%.

CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's proven effectiveness ...

CVS Health announced Monday that it plans to make Gilead Sciences' hepatitis C drugs the exclusive option for most of its consumers starting Wednesday. January 06, 2015 • Tribune News Service ...

CVS and Gilead Sciences strike an exclusive deal for hepatitis drugs Sovaldi and Harvoni. The total cost of treatment via Sovaldi can reach up to $84,000 for 12 weeks.

Gilead Sciences Inc., whose stock plummeted last month when Express Scripts Holding Co. chose to offer a competitor's hepatitis C drug, jumped Monday after CVS Health Corp. said Gilead's pill ...

CVS’s expansion into primary care is expected to drive long-term growth, while Gilead’s strong pipeline and market position in virology and oncology support its continued dividend growth.